Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement ...

Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization ...

Kymera Therapeutics KYMR is gearing up to announce its quarterly earnings on Monday, 2025-08-11. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

The company published two pieces of news the market found encouraging. It's begun dosing in a crucial early-stage clinical trial, and apparently has a new pipeline program in the works. Kymera is a ...

On Monday, June 2, Citi analysts increased the price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) from $52 to $60 and kept a “Buy” rating. This decision came after the release of positive ...

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...

On June 2, Kymera Therapeutics Inc. (NASDAQ:KYMR) received an upgrade from BofA analyst Tazeen Ahmad, who raised the stock's rating from Neutral to Buy and increased the price target to $51 from $44.

Kymera is a clinical-stage biotech that specializes in a mechanism known as targeted protein degradation in its medicines. On Tuesday, the company delivered encouraging news from the laboratory, ...